207 related articles for article (PubMed ID: 35253352)
1. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.
Crane JN; Xue W; Qumseya A; Gao Z; Arndt CAS; Donaldson SS; Harrison DJ; Hawkins DS; Linardic CM; Mascarenhas L; Meyer WH; Rodeberg DA; Rudzinski ER; Shulkin BL; Walterhouse DO; Venkatramani R; Weiss AR
Pediatr Blood Cancer; 2022 Jun; 69(6):e29644. PubMed ID: 35253352
[TBL] [Abstract][Full Text] [Related]
2. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
[TBL] [Abstract][Full Text] [Related]
3. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
[TBL] [Abstract][Full Text] [Related]
4. Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Routh JC; Dasgupta R; Chi YY; Shnorhavorian M; Tian J; Walterhouse DO; Breneman J; Wolden SL; Arndt CA; Hawkins DS; Rodeberg DA
Int J Cancer; 2020 Dec; 147(11):3168-3176. PubMed ID: 32525556
[TBL] [Abstract][Full Text] [Related]
5. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.
Shenoy A; Alvarez E; Chi YY; Li M; Shern JF; Khan J; Hiniker SM; Granberg CF; Hawkins DS; Parham DM; Teot LA; Rudzinski ER
Eur J Cancer; 2021 Jan; 143():127-133. PubMed ID: 33302115
[TBL] [Abstract][Full Text] [Related]
7. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies.
Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R
Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.
Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R
Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771
[TBL] [Abstract][Full Text] [Related]
10. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
12. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
[TBL] [Abstract][Full Text] [Related]
13. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.
Spalding AC; Hawkins DS; Donaldson SS; Anderson JR; Lyden E; Laurie F; Wolden SL; Arndt CA; Michalski JM
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):512-6. PubMed ID: 24074925
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Tian J; Gupta AA; Wolden SL; Routh JC; Casey DL; Dasgupta R; Hawkins DS; Rodeberg DA
Int J Cancer; 2020 Sep; 147(5):1419-1426. PubMed ID: 32012255
[TBL] [Abstract][Full Text] [Related]
15. Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.
Aye JM; Chi YY; Tian J; Rudzinski ER; Binitie OT; Dasgupta R; Wolden SL; Hawkins DS; Gupta AA
Pediatr Blood Cancer; 2020 May; 67(5):e28243. PubMed ID: 32124549
[TBL] [Abstract][Full Text] [Related]
16. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
17. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS
Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768
[TBL] [Abstract][Full Text] [Related]
18. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Li M; Wolden SL; Casey DL; Routh JC; Granberg CF; Binite O; Rudzinski ER; Hawkins DS; Venkatramani R; Rodeberg DA
Cancer; 2021 Jan; 127(2):275-283. PubMed ID: 33079399
[TBL] [Abstract][Full Text] [Related]
19. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.
Lin C; Donaldson SS; Meza JL; Anderson JR; Lyden ER; Brown CK; Morano K; Laurie F; Arndt CA; Enke CA; Breneman JC
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1764-70. PubMed ID: 21470795
[TBL] [Abstract][Full Text] [Related]
20. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.
Rosenberg AR; Anderson JR; Lyden E; Rodeberg DA; Wolden SL; Kao SC; Parham DM; Arndt C; Hawkins DS
Eur J Cancer; 2014 Mar; 50(4):816-23. PubMed ID: 24361229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
